GW Pharmaceuticals Plc (NASDAQ:GWPH) most recently reported quarterly actual earnings per share of $-0.73 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-1.73. The difference between the estimate and the actual EPS was $1 creating a surprise factor of 57.8%. Currently, the company has an impact score of 68. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.242. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.
In taking a look at where the stock might be headed, analysts have a consensus price target of $134.833 on the shares. The most bullish brokerage firm has a $182 target, while the most bearish sees the stock headed towards $40. This is according to the 6 estimates taken into consideration by Zacks Research.
In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.75. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 6 recommendations taking into account in order to arrive at this number. Of the 6, 4 have a Strong Buy rating and 1 are rating it a Buy.
GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions. The Company is developing a portfolio of cannabinoid medicines, of which the main product is Sativex, an oromucosal spray for the treatment of Multiple Sclerosis (MS) symptoms, cancer pain and neuropathic pain. The Company operates in three segments: Sativex Commercial, Sativex Research and Development and Pipeline Research and Development. The Company’s wholly owned subsidiaries include GW Pharma Limited, G-Pharm Limited, Cannabinoid Research Institute Limited, Guernsey Pharmaceuticals Limited and GWP Trustee Company Limited.
GW Pharmaceuticals Plc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.